Desmopressin Liquid

Based on clinical practice and authoritative guideline recommendations, it is mainly indicated for surgeries with low to moderate bleeding risk, especially in patients with mild coagulation abnormalities, platelet dysfunction, or prolonged bleeding time. Supported by clear clinical evidence, its applications include the following categories.

(1) Intraoperative Hemostasis in Surgeries Related to Bleeding Disorders
The is one of the first-line hemostatic agents for patients with mild hemophilia A and type 1 von Willebrand disease. These patients have a significantly higher intraoperative bleeding risk due to congenital deficiencies of factor Ⅷ or vWF. The product effectively compensates for coagulation defects and controls bleeding by rapidly increasing plasma levels of factor Ⅷ and vWF.

In clinical practice, preoperative oral administration of Desmopressin Liquid significantly shortens bleeding time, reduces intraoperative blood loss, and avoids transfusion in patients with mild hemophilia A undergoing minor procedures such as dental surgery or skin mass excision. For patients with type 1 von Willebrand disease-especially children and the elderly-the convenience of the liquid formulation is even more pronounced, allowing weight-based precise dosing and lower adverse reaction risk.
Note: The product is contraindicated in patients with type 2B von Willebrand disease to avoid thrombocytopenia and aggravated bleeding.

(2) Adjunctive Intraoperative Hemostasis in Non‑Bleeding Disorder Surgeries
In surgeries for non‑bleeding disorders, the product can serve as an adjuvant hemostatic agent for patients at bleeding risk, reducing intraoperative blood loss and transfusion requirements. It is most widely used in otorhinolaryngological procedures, such as functional endoscopic sinus surgery and rhinoplasty, which involve highly vascularized, narrow anatomical spaces where hemostasis is challenging and surgical visibility directly affects outcomes.

A randomized controlled trial (RCT) showed that patients receiving preoperative desmopressin (including the liquid formulation) had significantly less intraoperative bleeding, better surgical field visibility, higher surgeon satisfaction, and no severe adverse reactions. Additionally, in medium‑to‑small orthopedic and urological procedures, the product improves coagulation and helps control bleeding in patients with prolonged bleeding time due to uremia, liver cirrhosis, or other conditions, reducing postoperative complications such as hematoma and bleeding.

(3) Intraoperative Hemostasis in Special Populations
The liquid formulation gives it unique advantages for intraoperative hemostasis in children, the elderly, and other special populations.
Children often cannot swallow tablets and require precise microdosing based on low body weight. Desmopressin Liquid can be accurately measured with an oral syringe and flexibly adjusted, avoiding adverse reactions from overdosage. Its mild mechanism minimally affects the normal coagulation system in children, providing high safety for intraoperative hemostasis in those aged 6 years and older, such as during tonsillectomy or dental procedures.

Elderly patients frequently have comorbidities (hypertension, diabetes, renal insufficiency) and may have impaired coagulation or platelet function, with poor tolerance to injections. Oral administration avoids injections and discomfort, while precise dose titration reduces risks of fluid retention and hyponatremia from inappropriate dosing, matching the physiological status of elderly patients.

Compared with injectable desmopressin and other traditional intraoperative hemostatic agents, Desmopressin Liquid offers distinct advantages in convenience, precision, and safety, representing a superior clinical option.
• Convenience: As a ready-to-use oral liquid, it requires no injection by medical staff and can be self‑administered or given with assistance. It is especially useful when preoperative injection is difficult or anatomically unfeasible, reducing injection-related complications such as puncture injury and infection, and lowering the operational burden on healthcare providers.

• Precision: It enables precise microdose titration, allowing flexible adjustment according to patient weight, bleeding risk, and surgery type, overcoming the fixed‑dose limitation of solid forms. This ensures hemostatic efficacy while minimizing overdosage-related adverse reactions, particularly for children and the elderly, filling a clinical gap in precise intraoperative hemostasis.

• Safety: It enhances the body's intrinsic coagulation without directly altering prothrombin time or activated partial thromboplastin time, resulting in mild effects on normal hemostasis and a low, manageable adverse reaction rate. Oral administration also avoids injection-related allergic reactions.
Clinically, the product reduces intraoperative blood loss, transfusion requirements, and operative time; improves surgical visibility; lowers postoperative bleeding and hematoma; accelerates recovery; and reduces medical costs. Its liquid formulation expands the scope of desmopressin use in intraoperative hemostasis, especially for special populations, supporting individualized, convenient regimens and driving the development of precise, safe hemostatic care.

Although Desmopressin Oral Solution has a favorable safety profile, it carries defined clinical risks, the most serious and concerning being fluid retention and hyponatremia. By enhancing renal water reabsorption, insufficient fluid restriction during treatment can cause water intoxication and hyponatremia. Mild manifestations include headache, nausea, and fatigue; severe cases may lead to convulsions, coma, or even death, with higher risk in children, the elderly, and patients with fluid‑electrolyte imbalance.

Other mild adverse reactions may include headache, flushing, abdominal pain, and nausea; dizziness and skin allergy are rare. Pediatric patients may experience emotional disturbances such as hyperactivity or aggressiveness.
The drug has clear contraindications: it is contraindicated in type 2B von Willebrand disease, habitual polydipsia, cardiac insufficiency, and other conditions, as inappropriate use may worsen the underlying disease. Overdosage can lead to severe events such as pulmonary edema and oliguria, requiring prompt symptomatic treatment.